GnRH-I |
Catalog No.GC34264
One-Click Copy Product Info
|
GnRH-I is a neuropeptide capable of regulating the release of gonadotropins, used to modulate the physiological functions of the reproductive system.
Products are for research use only. Not for human use. We do not sell to patients.
Sample solution is provided at 25 µL, 10mM.
_1-3.$$$39978408@51.jpg');)
_1-9.$$$38538795@65.jpg');)
_1-9.$$$39112701@51.jpg');)
_1-7.$$$37316672@70.jpg');)
_366-372.$$$36198801@70.jpg');)
.$$$38565142@65.jpg');)
_1867-1883.$$$33248023@67.jpg');)
_eads6055.$$$39977546@45.jpg');)
_eadm9805.$$$40080571@45.jpg');)
_eadj3020.$$$39666821@45.jpg');)
_1-20.$$$39757301@28.jpg');)
_1-24.$$$38898113@28.jpg');)
_273-287.$$$36806353@46.jpg');)
_1-16.$$$37156877@44.jpg');)
_1-19.$$$37460805@44.jpg');)
_1291-1307.$$$34518654@46.jpg');)
GnRH-I is a neuropeptide capable of regulating the release of gonadotropins, used to modulate the physiological functions of the reproductive system[1]. GnRH-I stimulates the anterior pituitary to release gonadotropins, thereby regulating the synthesis and secretion of gonadal hormones and maintaining reproductive endocrine balance[2]. GnRH-I can be used to study the regulatory mechanisms of the hypothalamic-pituitary-gonadal (HPG) axis and its role in reproductive-related diseases[3]. GnRH-I may also play a significant role in the growth of ovarian tumors[4].
In vitro, GnRH-I (3nM) stimulation of gonadotropin cells from neonatal rat pituitary for 3 hours significantly promotes the secretion of luteinizing hormone (LH) and follicle-stimulating hormone (FSH). This process depends on the activation of intracellular calcium signaling and cyclic nucleotide signaling pathways[5]. Treatment of human extravillous cytotrophoblasts (EVTs) with GnRH-I (0.1–100nM) for 24 hours significantly upregulates the mRNA and protein expression levels of urokinase-type plasminogen activator (uPA), while downregulating the expression of plasminogen activator inhibitor-1 (PAI-1). This enhances extracellular matrix degradation capacity, thereby promoting the invasive potential of trophoblast cells during early pregnancy[6].
In vivo, a single intravenous bolus of GnRH-I (0.01–10μg/kg body weight) administered to female rhesus monkeys aged 8–12 months and 21–23 months significantly promotes the release of plasma luteinizing hormone (LH), with younger individuals showing greater sensitivity[7].
References:
[1] Cheng CK, Leung PC. Molecular biology of gonadotropin-releasing hormone (GnRH)-I, GnRH-II, and their receptors in humans. Endocr Rev. 2005 Apr;26(2):283-306.
[2] Leung PC, Cheng CK, Zhu XM. Multi-factorial role of GnRH-I and GnRH-II in the human ovary. Mol Cell Endocrinol. 2003 Apr 28;202(1-2):145-53.
[3] Kern J, Schilling D, Schneeweis C, et al. Identification of the unfolded protein response pathway as target for radiosensitization in pancreatic cancer. Radiother Oncol. 2024 Feb;191:110059.
[4] Kang SK, Choi KC, Yang HS, et al. Potential role of gonadotrophin-releasing hormone (GnRH)-I and GnRH-II in the ovary and ovarian cancer. Endocr Relat Cancer. 2003 Jun;10(2):169-77.
[5] Balík A, Jindřichová M, Bhattacharyya S, et al. GnRH-I and GnRH-II-induced calcium signaling and hormone secretion in neonatal rat gonadotrophs. Physiol Res. 2009;58(5):709-716.
[6] Chou CS, Zhu H, Shalev E, et al. The effects of gonadotropin-releasing hormone (GnRH) I and GnRH II on the urokinase-type plasminogen activator/plasminogen activator inhibitor system in human extravillous cytotrophoblasts in vitro. J Clin Endocrinol Metab. 2002 Dec;87(12):5594-603.
[7] Densmore VS, Urbanski HF. Relative effect of gonadotropin-releasing hormone (GnRH)-I and GnRH-II on gonadotropin release. J Clin Endocrinol Metab. 2003 May;88(5):2126-34.
| Cell experiment [1]: | |
Cell lines | Human extravillous cytotrophoblasts (EVTs) |
Preparation Method | EVTs were cultured in DMEM supplemented with 10% fetal bovine serum at 37°C, 5% CO₂. Cells were treated with GnRH-I at concentrations ranging from 0.1 to 100nM for 24 hours. |
Reaction Conditions | 0.1–100nM; 24h |
Applications | GnRH-I significantly increased urokinase-type plasminogen activator (uPA) mRNA and protein expression in a dose-dependent manner, with maximal effects observed at 100nM. Concurrently, GnRH-I reduced plasminogen activator inhibitor-1 (PAI-1) mRNA and protein levels, altering the uPA/PAI-1 ratio to promote trophoblast invasiveness. |
| Animal experiment [2]: | |
Animal models | Rhesus monkeys (Macaca mulatta) |
Preparation Method | Monkeys were intravenously administered a single bolus injection of GnRH-I at doses of 0.01, 0.1, 1, or 10μg/kg body weight during the midluteal phase. Blood samples were collected remotely via vascular catheters at -10, 0, 10, 20, 30, 60, and 120 minutes post-injection. |
Dosage form | 0.01–10μg/kg; i.v. |
Applications | GnRH-I significantly increased plasma luteinizing hormone (LH) concentrations in a dose-dependent manner, with peak responses observed within 10 minutes. The LH release was more pronounced in young animals compared to old monkeys, indicating age-related sensitivity differences. |
References: | |
| Cas No. | SDF | ||
| Canonical SMILES | Pyr-His-Trp-Ser-Tyr-Gly-Leu-Arg-Pro-Gly-NH2 | ||
| Formula | C50H75N17O13 | M.Wt | 1182.32 |
| Solubility | Water : 50 mg/mL (42.29 mM) | Storage | -20°C, protect from light |
| General tips | Please select the appropriate solvent to prepare the stock solution according to the
solubility of the product in different solvents; once the solution is prepared, please store it in
separate packages to avoid product failure caused by repeated freezing and thawing.Storage method
and period of the stock solution: When stored at -80°C, please use it within 6 months; when stored
at -20°C, please use it within 1 month. To increase solubility, heat the tube to 37°C and then oscillate in an ultrasonic bath for some time. |
||
| Shipping Condition | Evaluation sample solution: shipped with blue ice. All other sizes available: with RT, or with Blue Ice upon request. | ||
| Prepare stock solution | |||
|
1 mg | 5 mg | 10 mg |
| 1 mM | 845.8 μL | 4.229 mL | 8.4579 mL |
| 5 mM | 169.2 μL | 845.8 μL | 1.6916 mL |
| 10 mM | 84.6 μL | 422.9 μL | 845.8 μL |
Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)
g
μL
Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)
Calculation results:
Working concentration: mg/ml;
Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )
Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL saline, mix and clarify.
Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.
Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such as vortex, ultrasound or hot water bath can be used to aid dissolving.
3. All of the above co-solvents are available for purchase on the GlpBio website.
Quality Control & SDS
- View current batch:
- Purity: >98.00% Appearance: A solid
- COA (Certificate of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Average Rating: 5 (Based on Reviews and 22 reference(s) in Google Scholar.)